SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaini...
Source: Nuklearmedizin - April 9, 2024 Category: Radiology Authors: Christoph-Ferdinand Wielenberg Johannes Christian Fostitsch Christian Volz Reinhard Marks Kerstin Michalski Ralph W äsch Robert Zeiser Juri Ruf Philipp T Meyer Claudius Klein Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
Improving resource utilization: Axillary lymph node core biopsy triaging for lymphoma
CONCLUSIONS: Our enterprise overused hematopathology resources in the evaluation of AxLNCB performed in the study period. Our process could improve from the application of a simple tool generated from this cohort to predict percent risk of the specimen containing hematologic malignancy using patient characteristics easily found via routine chart review.PMID:38591770 | DOI:10.1093/ajcp/aqae032 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - April 9, 2024 Category: Pathology Authors: Carl Dernell John Astle Abraham Bogachkov Shelly Reimer Anubha Wadhwa Shadie S Majidi Bethany Canales Julie M Jorns Source Type: research
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaini...
Source: Nuklearmedizin - April 9, 2024 Category: Radiology Authors: Christoph-Ferdinand Wielenberg Johannes Christian Fostitsch Christian Volz Reinhard Marks Kerstin Michalski Ralph W äsch Robert Zeiser Juri Ruf Philipp T Meyer Claudius Klein Source Type: research
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Clin Lymphoma Myeloma Leuk. 2024 Mar 18:S2152-2650(24)00113-7. doi: 10.1016/j.clml.2024.03.006. Online ahead of print.ABSTRACTHigher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents.Higher-risk myelodysplastic syndromes (HR-...
Source: Clinical Lymphoma and Myeloma - April 9, 2024 Category: Cancer & Oncology Authors: Michael J Hochman Amy E DeZern Source Type: research
Improving resource utilization: Axillary lymph node core biopsy triaging for lymphoma
CONCLUSIONS: Our enterprise overused hematopathology resources in the evaluation of AxLNCB performed in the study period. Our process could improve from the application of a simple tool generated from this cohort to predict percent risk of the specimen containing hematologic malignancy using patient characteristics easily found via routine chart review.PMID:38591770 | DOI:10.1093/ajcp/aqae032 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Carl Dernell John Astle Abraham Bogachkov Shelly Reimer Anubha Wadhwa Shadie S Majidi Bethany Canales Julie M Jorns Source Type: research
Improving resource utilization: Axillary lymph node core biopsy triaging for lymphoma
CONCLUSIONS: Our enterprise overused hematopathology resources in the evaluation of AxLNCB performed in the study period. Our process could improve from the application of a simple tool generated from this cohort to predict percent risk of the specimen containing hematologic malignancy using patient characteristics easily found via routine chart review.PMID:38591770 | DOI:10.1093/ajcp/aqae032 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Carl Dernell John Astle Abraham Bogachkov Shelly Reimer Anubha Wadhwa Shadie S Majidi Bethany Canales Julie M Jorns Source Type: research
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
CONCLUSION: In this pretreated cohort, osimertinib did not meet the prespecified end point threshold for efficacy, but responses were seen in a neuroendocrine carcinoma with an EGFR exon 20 S768T and exon 18 G719C mutation and an epithelial carcinoma with an EGFR D770_N771insSVD mutation. Osimertinib was well tolerated and had a safety profile consistent with previous studies.PMID:38591867 | PMC:PMC10896470 | DOI:10.1200/PO.23.00454 (Source: Ann Oncol)
Source: Ann Oncol - April 9, 2024 Category: Cancer & Oncology Authors: Monica F Chen Zihe Song Helena A Yu Lecia V Sequist Christine M Lovly Edith P Mitchell Jeffrey A Moscow Robert J Gray Victoria Wang Lisa M McShane Larry V Rubinstein David R Patton P Mickey Williams Stanley R Hamilton Yoshie Umemura James V Tricoli Barbar Source Type: research
Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival - a Swedish Lymphoma Register Study
Acta Oncol. 2024 Apr 9;63:164-168. doi: 10.2340/1651-226X.2024.35238.ABSTRACTBACKGROUND & PURPOSE: The COVID-19 pandemic posed a large challenge for healthcare systems across the world. Comprehensive data on the impact of the COVID-19 pandemic on incidence and mortality in lymphoma are lacking.PATIENTS/METHODS: Using data from the Swedish lymphoma register, we compare incidence and 1-year survival of lymphoma patients in Sweden before (2017-2019) and during the pandemic (2020 and 2021).RESULTS: Fewer patients were diagnosed with lymphomas during March-June 2020, but the annual incidence rates for 2020 and 2021 were similar...
Source: Acta Oncologica - April 9, 2024 Category: Cancer & Oncology Authors: Sara Ekberg Daniel Molin Simon Pahnke Fanny Bergstr öm Elsa Br ånvall Karin E Smedby Tove W ästerlid Source Type: research
Successful treatment of severe splenic lymphoma ‑associated hemophagocytic syndrome by splenectomy and subsequent chemotherapy: A case report
Oncol Lett. 2024 Mar 22;27(5):222. doi: 10.3892/ol.2024.14355. eCollection 2024 May.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) represents a fatal immunopathology derived from excessive inflammatory reactions. In particular, lymphoma-associated hemophagocytic syndrome (LAHS) is associated with a dismal prognosis. The current study presented a challenging case of splenic LAHS. A 71-year-old man presented with fatigue and anorexia. Laboratory test results revealed anemia, thrombocytopenia, lactate dehydrogenase elevation and markedly elevated levels of ferritin (6,210 ng/ml) and soluble interleukin 2 receptor (sIL-2R; 1...
Source: Oncology Letters - April 9, 2024 Category: Cancer & Oncology Authors: Hideyuki Masui Maki Shindo Yuta Inoue Maki Sugiyama Atsushi Ueda Takero Shindo Kae Okoshi Koichi Kinoshita Source Type: research
Estrogen receptors alpha and beta expression in different canine cancer types with an emphasis on hematopoietic malignancies
Vet Res Commun. 2024 Apr 10. doi: 10.1007/s11259-024-10368-2. Online ahead of print.ABSTRACTEstrogen receptors (ERs) are located in both healthy and neoplastic tissues. The type of estrogen receptor expressed varies depending on its location, tumor type, and species. Estrogen action is mediated by binding to ER and activating the transcriptional and signaling processes that result in the control of gene expression. There are two main types of estrogen receptors: ER alpha (ERα) and ER beta (ERβ). Both receptors are functionally different, they may act antagonistically and are distributed in different tissues but their str...
Source: Cell Research - April 9, 2024 Category: Cytology Authors: Katarzyna Bugiel-Stabla Chiara Agnoli Aleksandra Pawlak Source Type: research
Improving resource utilization: Axillary lymph node core biopsy triaging for lymphoma
CONCLUSIONS: Our enterprise overused hematopathology resources in the evaluation of AxLNCB performed in the study period. Our process could improve from the application of a simple tool generated from this cohort to predict percent risk of the specimen containing hematologic malignancy using patient characteristics easily found via routine chart review.PMID:38591770 | DOI:10.1093/ajcp/aqae032 (Source: American Journal of Clinical Pathology)
Source: American Journal of Clinical Pathology - April 9, 2024 Category: Pathology Authors: Carl Dernell John Astle Abraham Bogachkov Shelly Reimer Anubha Wadhwa Shadie S Majidi Bethany Canales Julie M Jorns Source Type: research
FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL)
This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaini...
Source: Nuklearmedizin - April 9, 2024 Category: Radiology Authors: Christoph-Ferdinand Wielenberg Johannes Christian Fostitsch Christian Volz Reinhard Marks Kerstin Michalski Ralph W äsch Robert Zeiser Juri Ruf Philipp T Meyer Claudius Klein Source Type: research
Improving resource utilization: Axillary lymph node core biopsy triaging for lymphoma
CONCLUSIONS: Our enterprise overused hematopathology resources in the evaluation of AxLNCB performed in the study period. Our process could improve from the application of a simple tool generated from this cohort to predict percent risk of the specimen containing hematologic malignancy using patient characteristics easily found via routine chart review.PMID:38591770 | DOI:10.1093/ajcp/aqae032 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Carl Dernell John Astle Abraham Bogachkov Shelly Reimer Anubha Wadhwa Shadie S Majidi Bethany Canales Julie M Jorns Source Type: research
